CS-834 is a novel oral carbapenem antibiotic. This compound is an ester-type prodrug of the active metabolite R-95867. The antibacterial activity of R-95867 was tested against 1,323 clinical isolates of 35 species and was compared with those of oral cephems, i.e., cefteram, cefpodoxime, cefdinir, and cefditoren, and that of a parenteral carbapenem, imipenem. R-95867 exhibited a broad spectrum of activity covering both grampositive and -negative aerobes and anaerobes. Its activity was superior to those of the other compounds tested against most of the bacterial species tested. R-95867 showed potent antibacterial activity against clinically significant pathogens: methicillin-susceptible Staphylococcus aureus including ofloxacin-resistant strains, Streptococcus pneumoniae including penicillin-resistant strains, Clostridium perfringens, Neisseria spp., Moraxella catarrhalis, most members of the family Enterobacteriaceae, and Haemophilus influenzae (MIC at which 90% of strains are inhibited, <0.006 to 0.78 g/ml). R-95867 was quite stable to hydrolysis by most of the ␤-lactamases tested except the metallo-␤-lactamases from Stenotrophomonas maltophilia and Bacteroides fragilis. R-95867 showed potent bactericidal activity against S. aureus and Escherichia coli. Penicillin-binding proteins 1 and 4 of S. aureus and 1Bs, 2, 3, and 4 of E. coli had high affinities for R-95867. The in vivo efficacy of CS-834 was evaluated in murine systemic infections caused by 16 strains of gram-positive and -negative pathogens. The efficacy of CS-834 was in many cases superior to those of cefteram pivoxil, cefpodoxime proxetil, cefdinir, and cefditoren pivoxil, especially against infections caused by S. aureus, penicillin-resistant S. pneumoniae, E. coli, Citrobacter freundii, and Proteus vulgaris. Among the drugs tested, CS-834 showed the highest efficacy against experimental pneumonia in mice caused by penicillin-resistant S. pneumoniae.
Several expanded spectrum cephem antibiotics have been developed as orally administered forms and have been shown to be clinically useful, especially against respiratory tract infections. Cefdinir, cefteram pivoxil, cefpodoxime proxetil, and cefditoren pivoxil were among such orally active cephems. The three of them are administered as ester-type prodrugs. They have been reported to have potent antibacterial activity against various species of bacteria (14, 18, 26, 27) . They show, however, only moderate activities against some gram-positive cocci, such as Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, and some members of the family Enterobacteriaceae, such as Citrobacter freundii, Enterobacter spp., and Serratia marcescens. On the other hand, cephemresistant pathogens have increased in number, possibly because of the widespread use of ␤-lactam antibiotics (2, 5, 12, 19, 20) . Carbapenems, such as imipenem, have been developed as parenteral drugs for the treatment of severe infections and have been recognized as antibiotics with excellent antibacterial activity against a broad spectrum of bacteria, including cephem-resistant organisms (13, 15, 16) . They have been shown to be useful against such cephem-resistant organisms. Carbapenems, however, are not yet available as an orally absorbable form.
CS-834, (ϩ)-{pivaloyloxymethyl(4R,5S,6S)-6-[(R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[(R)-5-oxopyrrolidin-3-yl]thio]-
1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate}, is a novel orally absorbable carbapenem candidate. This carbapenem has a methyl group at the 1␤ position of the carbapenem nucleus, like meropenem. The 1␤-methyl group confers to carbapenems a higher degree of stability to dehydropeptidase I and stronger activity against gram-negative organisms. This compound is an ester-type prodrug with a pivaloyloxymethyl group. Its active metabolite, R-95867, is released into the blood when CS-834 is absorbed from the intestinal wall. Figure 1 shows the chemical structures of CS-834 and R-95867. In this study, we investigated the in vitro and in vivo antibacterial activities of R-95867 and CS-834 and compared them with those of oral cephems, i.e., cefteram, cefpodoxime, cefdinir, and cefditoren, and with that of a parenteral carbapenem, imipenem.
(This work was presented in part at the 36th Interscience 
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Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La., 15 to 18 September 1996 [17, 28] ).
MATERIALS AND METHODS

Antibiotics.
The following compounds were synthesized at Sankyo Research Laboratories, Tokyo, Japan: CS-834, sodium salt of R-95867, cefpodoxime, cefpodoxime proxetil, cefteram, and cefditoren. The other compounds were obtained from the indicated sources: cefteram pivoxil, Toyama Chemical Co., Ltd., Tokyo, Japan; cefdinir, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan; and cefditoren pivoxil, Meiji Seika Kaisha, Ltd., Tokyo, Japan.
Bacterial strains. The bacterial strains used in this study were isolated from clinical specimens in Japanese hospitals between 1990 and 1995 and were stored frozen at Ϫ80°C in our laboratory.
Susceptibility testing. MICs were determined by the usual twofold agar dilution technique (6) . Mueller-Hinton II agar (Becton Dickinson Microbiology Systems, Cockeysville, Md.) was used as a medium for all species of bacteria with the following exceptions. Pearlcore heart infusion agar (HIA; Eiken Chemical Co., Ltd., Tokyo, Japan) supplemented with 5% defibrinated horse blood was used for streptococci, HIA supplemented with 5% Fildes enrichment (Difco Laboratories, Detroit, Mich.) was used for Haemophilus influenzae, and chocolate HIA was used for Moraxella catarrhalis. GAM agar (Nissui Seiyaku Co., Ltd., Tokyo, Japan) was used for obligate anaerobic bacteria. The inoculum size was 10 4 CFU per spot (5 l). The inoculated plates were incubated at 37°C for 18 to 24 h. Neisseria spp. were incubated in 5% CO 2 at 37°C for 24 h. Obligate anaerobic bacteria were incubated in an anaerobic chamber (Forma Scientific, Marietta, Ohio) at 37°C for 24 to 48 h. Killing curve tests. The bactericidal activities of R-95867 and reference antibiotics were determined with S. aureus 209P JC-1 and Escherichia coli NIHJ JC-2. An overnight culture in heart infusion broth (HIB; Eiken Chemical Co., Ltd.) was diluted with fresh HIB and was incubated at 37°C with shaking to yield approximately 10 6 to 10 7 CFU/ml. Antibiotic solutions were then added to respective final concentrations of 1/16, 1/4, 1, 4, and 16 times the MIC. Sample aliquots were withdrawn at 1, 2, and 4 h after incubation at 37°C with shaking and were serially diluted with saline. One hundred microliters of the diluents was spread onto HIA plates, and the plates were incubated at 37°C for 24 h. The viable cell numbers were determined by counting the number of colonies on the plates. Drug carryover did not affect colony formation, since all samples were diluted at least 100-fold with saline (detection limit, 10 3 CFU/ml). The viability of each culture was checked after 24 h of drug exposure by plating 100 l of the sample onto HIA plates and incubating at 37°C for 24 h.
Stability to ␤-lactamases. Various types of ␤-lactamases were prepared by the method reported previously (1, 9, (22) (23) (24) (25) or were purchased commercially (Bacillus cereus; Sigma Chemical Co., St. Louis, Mo.). The stabilities of the antibiotics to ␤-lactamases were determined by the spectrophotometric assay reported by Waley (30) . The change in absorbance was monitored after the addition of a test enzyme to the reaction mixture. The wavelengths used were as follows: (29) . The membrane suspensions were adjusted to protein concentrations of 8 and 15 mg per ml for S. aureus and E. coli, respectively. The affinity for penicillin-binding proteins (PBPs) was assayed by the method of Spratt (21), with some modifications (27) Murine systemic infection model. The therapeutic efficacies of CS-834 and the reference compounds were evaluated with a murine systemic infection model. Male ddY mice weighing 19 to 21 g (SLC Japan Inc., Shizuoka, Japan) were infected intraperitoneally with 0.2 ml of bacterial suspension. The challenge doses were those that caused 100% mortarity between the 3rd and 5th days after infection (see Table 5 ). They ranged between 3 and 25 times of 50% lethal doses (LD 50 s) for all pathogens except S. pneumoniae (150 to 200 LD 50 s). CS-834, cefteram pivoxil, cefdinir, cefpodoxime proxetil, and cefditoren pivoxil were administered orally as a 0.2-ml suspension of 0.5% sodium carboxymethyl cellulose (Kanto Chemical Co., Inc., Tokyo, Japan) immediately and 4 h after infection. Seven mice were used for each dose. Values of 50% effective doses (ED 50 s) and 95% confidence limits were calculated by the probit method (3) from the survival rates on the 5th day after infection.
Murine model of pneumonia caused by S. pneumoniae. Experimental pneumonia was induced in male ddY mice weighing 19 to 21 g (SLC Japan Inc.) by infecting them penicillin-susceptible S. pneumoniae 2132 and 8236 (MICs of benzylpenicillin for both strains, Յ0.006 g/ml) and penicillin-resistant S. pneumoniae 9605 and 9601 (MICs of benzylpenicillin for both strains, 1.56 g/ml). For penicillin-resistant S. pneumoniae infections, cyclophosphamide (Shionogi Pharmaceutical Co., Ltd., Osaka, Japan) was administered intravenously 3 days before the infection at a dose of 200 mg/kg of body weight to establish the infection successfully. The lungs of the mice were infected through the nares with 50 l of a bacterial suspension. The challenge doses were those that caused 100% mortality between the 8th and 14th days after infection (see Table 6 ). It was quite difficult to control the challenge doses precisely so that the same mortality rate was achieved on the same day, because the toxicity of penicillin-resistant S. pneumoniae was low. Antibiotics were administered orally at 1 and 6 h after the bacterial challenge. In the case of penicillin-resistant S. pneumoniae, four more antibiotic administrations were done at 24, 32, 48, and 52 h after the bacterial challenge. Seven mice were used for each dose. The ED 50 s and 95% confidence limits were calculated by the probit method (3) from the survival rates at 14 days after infection.
RESULTS
Antibacterial activity. The antibacterial activity of R-95867 against 1,323 clinical isolates of 35 species (4 to 71 strains of each species) was determined and compared with those of cefteram, cefpodoxime, cefdinir, cefditoren, and imipenem. Table 1 summarizes the MIC ranges and MICs at which 50% and 90% of the clinical isolates were inhibited (MIC 50 s and MIC 90 s, respectively). R-95867 exhibited a broad antibacterial spectrum, with activity against gram-positive and -negative aerobes and anaerobes. The antibacterial activity of R-95867 was superior to those of the reference cephems against most of the bacterial species tested. In comparison with imipenem, R-95867 was, in general, less active against gram-positive organisms and was more active against gram-negative organisms except Pseudomonas aeruginosa.
R-95867 was more active than the reference cephems against Staphylococcus spp., except that the MIC 90 of R-95867 was fourfold higher than that of cefdinir for methicillin-susceptible Staphylococcus epidermidis. In particular, against methicillin-susceptible S. aureus including ofloxacin-resistant strains, R-95867 showed potent activity (MIC 90 s for methicillin-susceptible S. aureus and ofloxacin-resistant S. aureus, 0.20 and 0.78 g/ml, respectively), whereas the cephems showed moderate activity. R-95867 showed only weak activity against methicillin-resistant strains of Staphylococcus spp., like the other antibiotics tested.
R-95867 showed potent activity against most streptococci including penicillin-resistant S. pneumoniae (MIC 90 s, 0.012 to 0.39 g/ml) but not against Streptococcus mitis and Streptococcus sanguis. Its activity was comparable or superior to those of the cephems. R-95867 exhibited stronger activity than the cephems against penicillin-susceptible, -intermediate, and -resistant S. pneumoniae, whereas it was less active than imipenem. R-95867 exhibited modest activity against Enterococcus faecalis, including ofloxacin-resistant strains (MIC 90 s for both E. faecalis and ofloxacin-resistant E. faecalis, 12.5 g/ml), although its activity was stronger than those of the cephems. The activity of R-95867 against Peptostreptococcus anaerobius (MIC 90 , 0.39 g/ml) was comparable to those of the cephems. R-95867 showed stronger activity than the cephems against Peptostreptococcus asaccharolyticus (MIC 90 , 0.05 g/ml), Peptostreptococcus magnus (MIC 90 , 0.10 g/ml), Propionibacterium acnes (MIC 90 , 0.20 g/ml), and Clostridium perfringens (MIC 90 , Յ0.006 g/ml).
R-95867 showed strong activity against gram-negative cocci including Neisseria gonorrhoeae (MIC 90 , 0.025 g/ml), M. catarrhalis (MIC 90 , 0.10 g/ml), and Neisseria meningitidis.
R-95867 showed consistently potent activity against the strains of the family Enterobacteriaceae, especially the more common clinically significant isolates, such as E. coli, Klebsiella spp., and Proteus spp. The MIC 90 s of R-95867 for the strains of the family Enterobacteriaceae tested were 0.025 to 0.78 g/ml except for those for Enterobacter cloacae (MIC 90 , 1.56 g/ml), S. marcescens (MIC 90 , 6.25 g/ml), and Providencia rettgeri (MIC 90 , 6.25 g/ml). The activity of R-95867 was stronger than those of the cephems against all members of the family Enterobacteriaceae, particularly against pathogens that commonly produce ␤-lactamases (e.g. C. freundii, Enterobacter spp., S. Continued on following page marcescens, and Morganella morganii). As far as we tested, no isolates produced a metallo-␤-lactamase. R-95867 showed weak activity against P. aeruginosa (MIC 50 and MIC 90 , 25 and 50 g/ml, respectively), whereas the cephems were inactive against this organism. Against H. influenzae, R-95867 was as active as cefpodoxime (MIC 90 , 0.39 g/ml) and was fourfold more active than cefdinir and imipenem, although it was less active than cefteram and cefditoren. Against Acinetobacter calcoaceticus, R-95867 showed moderate activity (MIC 90 , 3.13 g/ml), although its activity was stronger than those of the cephems. The MIC 90 s of R-95867 against Bacteroides fragilis and Fusoabacterium nucleatum were 1.56 and 0.05 g/ml, respectively, which were lower than those of the cephems.
R-95867 showed stronger activity than imipenem against C. perfringens, N. gonorrhoeae, E. coli, K. pneumoniae, Klebsiella oxytoca, Proteus vulgaris, Proteus mirabilis, M. morganii, Burkholderia cepacia, and H. influenzae.
Bactericidal activity. Figure 2 shows time-kill curves for R-95867, cefpodoxime, cefdinir, and cefditoren against S. aureus 209P JC-1 and E. coli NIHJ JC-2. R-95867 reduced the viable cell counts for S. aureus to 1/100 of the inoculum size within 2 h after exposure to the MIC and higher concentrations. Against E. coli, R-95867 at 4 and 16 times the MIC showed bactericidal activity stronger than those of the cephems.
Stability to ␤-lactamases. Table 2 shows the stabilities of R-95867, imipenem, cefteram, cefpodoxime, cefdinir, and cefditoren to hydrolysis by various types of ␤-lactamases. R-95867 was quite stable to hydrolysis by all ␤-lactamases tested except the metallo-␤-lactamases. R-95867 was hydrolyzed by the metallo-␤-lactamases produced by Stenotrophomonas maltophilia XM-9 and B. fragilis 44.
Binding to PBPs. Tables 3 and 4 show the binding of R-95867, cefteram, cefpodoxime, cefdinir, cefditoren, and imipenem to PBPs of S. aureus 123-1-2 and E. coli NIHJ JC-2, respectively. For S. aureus 123-1-2, PBPs 1 and 4 showed high affinities for R-95867. PBPs 2 and 3 showed no affinity for R-95867. In contrast, PBPs 2 and 3, as well as PBPs 1 and 4, showed high affinities for imipenem. In general, PBPs 2, 1, and 3 showed affinities for the cephems tested, but PBP 4 did not show a high degree of affinity for these cephems.
For E. coli, PBP 2 showed the highest affinity for R-95867, and PBPs 3, 1B, and 4 followed. PBP 5 also showed affinity for R-95867, as it did for imipenem. PBPs 3, 1A, and 1B showed a high degree of affinity for the cephems.
Efficacy against murine systemic infections. Table 5 shows the protective effects of CS-834, cefteram pivoxil, cefpodoxime proxetil, cefdinir, and cefditoren pivoxil against experimental murine systemic infections caused by a variety of pathogens. Among the antibiotics tested, CS-834 showed the most potent protective activity against infections caused by S. aureus Smith, S. aureus 560, S. epidermidis 1392, penicillin-resistant S. pneumoniae 9605, E. coli 704, E. coli 609, C. freundii 1231, P. vulgaris 1413, P. vulgaris 1417, and M. morganii 168. The protective effect of CS-834 was comparable to those of cefpodoxime proxetil, cefditoren pivoxil, and cefteram pivoxil and was stronger than that of cefdinir against infections caused by penicillin-susceptible S. pneumoniae 2132, Streptococcus pyogenes 1412, and P. mirabilis 1262. Against S. marcescens 1850 infection, CS-834 was as active as cefteram pivoxil and cefpodoxime proxetil and was more active than cefdinir and cefdi- toren pivoxil. CS-834 showed greater efficacy than cefteram pivoxil, cefdinir, and cefditoren pivoxil against infections caused by K. pneumoniae 866 and K. oxytoca 2775, whereas the efficacy of CS-834 was comparable to that of cefpodoxime proxetil. Efficacy against experimental murine pneumonia caused by S. pneumoniae. Table 6 shows the protective effects of CS-834, cefteram pivoxil, cefpodoxime proxetil, cefdinir, and cefditoren pivoxil against experimental pneumonia caused by penicillinsusceptible and -resistant S. pneumoniae. The therapeutic efficacy of CS-834 against pneumonia caused by penicillin-susceptible S. pneumoniae was superior to that of cefdinir, was comparable to those of cefteram pivoxil and cefditoren pivoxil, and was inferior to that of cefpodoxime proxetil. CS-834, however, showed the strongest therapeutic efficacy against pneumonia caused by penicillin-resistant S. pneumoniae.
DISCUSSION
R-95867, the active metabolite of CS-834, showed potent antibacterial activity with a broad antibacterial spectrum that encompasses a wide range of gram-positive and -negative aerobic and anaerobic pathogens. In comparison with the cephem antibiotics tested, a characteristic of R-95867 is its strong activity against some gram-positive cocci, such as S. aureus and penicillin-resistant S. pneumoniae, and some members of the family Enterobacteriaceae, such as C. freundii, E. cloacae, Enterobacter aerogenes, and S. marcescens. R-95867 was very stable to most types of ␤-lactamases except metallo-␤-lactamases. In particular, R-95867 showed a higher degree of stability to ␤-lactamases of strains of the family Enterobacteriaceae, such as C. freundii, E. cloacae, S. marcescens, M. morganii, and P. vulgaris, than the cephem antibiotics did. This suggests that the high degree of stability of R-95867 to these ␤-lactamases is one reason for its potent activity against clinical isolates of the family Enterobacteriaceae.
PBPs 1 and 4 of S. aureus showed high affinities for R-95867, although PBPs 2 and 3 did not. It has been reported that PBPs 2 and 3 are essential for bacterial growth in S. aureus (10, 11) , whereas a defect in PBPs 1 or 4 was not lethal (7, 8) . This is probably one reason that R-95867 showed stronger bactericidal activity against S. aureus than the other cephems tested, for which PBP 3 and 2 showed a high affinity. E. coli PBPs also showed unique affinities for R-95867 compared with their affinities for the cephems. In E. coli, PBP 2 showed the highest affinity for R-95867, followed by PBPs 3, 1B, and 4. R-95867 induced slightly elongated spherical forms but did not induce long filamentous cells, which are usually found when cells are treated with the cephems (28) . This is consistent with the characteristic morphological alterations associated with inhibition of PBPs 2 and 3, respectively.
The therapeutic efficacy of CS-834 was superior to those of the reference cephems tested against systemic infections caused by most of the strains tested. These results are considered to reflect the potent in vitro antibacterial activity of R-95867. CS-834 also showed the better therapeutic efficacy against experimental pneumonia caused by penicillin-resistant S. pneumoniae, suggesting that this antibiotic would be clinically useful, because the incidence of penicillin-resistant S. pneumoniae has increased and has become a serious problem (2, 5, 20) .
In conclusion, the new orally administered carbapenem CS-834 has been judged to be a promising compound for further evaluation. Its in vitro spectrum covers all bacteria causing infections encountered in general practice and in hospital outpatients. Clinical studies with CS-834 are in progress in Japan and will start soon in the United States. 
